Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
NUTROPIN is a recombinant human growth hormone (somatropin) approved in 1993 for treating growth hormone deficiency and related growth disorders. Administered by injection, it replaces or supplements endogenous growth hormone to promote normal linear growth and metabolic function. The cytokine modality enables direct physiological hormone replacement therapy.
As LOE approaches, the brand team is likely focused on lifecycle extension strategies, patient retention, and managed transition planning rather than growth investment.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Post-Marketing Study of the Immunogenicity of Somatropin (Ribosomal Deoxyribo Nucleic Acid [rDNA] Origin) Injection (Nutropin AQ®) in Children With Growth Hormone Deficiency
Bioequivalence of Two Products (Norditropin® Versus Nutropin AQ®) in Healthy Adult Volunteers
A Study to Evaluate Growth in Participants Treated With Somatropin (Nutropin) Using NuSpin Device
A Post Marketing Surveillance Program for NutropinAq® in Paediatric Growth Disorders
A Post Marketing Surveillance Study for NutropinAq® in Adults With Growth Hormone Deficiency
Worked on NUTROPIN at Roche? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on NUTROPIN offers stability in a mature, well-understood market but limited growth opportunity as LOE approaches. Career progression likely emphasizes payer strategy, market defense, and transition planning rather than commercial expansion.